Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Harry A. Smith is active.

Publication


Featured researches published by Harry A. Smith.


Clinical Research and Regulatory Affairs | 1988

Erratum: &&A Survey of Drug Products Removed from the Market

Harry A. Smith

AbstractA survey of drug product removal from the market was conducted for the years of 1980–1984 covering 24 firms and 95 products. The questionnaires were mailed to 46 firms and covered 200 products, 152 single entities and 48 combination products. Useable responses included 71 single entities and 24 combination products. The percentages of mode of product approval for the final sample were NDA 50%; ANDA, 16%, and grandfather clause, 34%. The mean life span was 20.4 years. The primary reasons for removal of the products were economic, 65%; regulatory, 27% and other, 8%. There was a significant difference in the approval modes and a marginally significant difference for the reasons of product removal from the market for the two product types. The reason for product removal was different for products approved under the three modes of approval, but this was only marginally significant statistically. The X2 test was used for these determinations. More drug products were removed from the market than were add...


Clinical Research and Regulatory Affairs | 1987

A Survey of Drug Products Removed from the Market

Harry A. Smith

AbstractA survey of drug product removal from the market was conducted for the years of 1980-1984 covering 24 firms and 95 products. the questionnaires were mailed to 46 firms and covered 200 products, 152 single entities and 48 combination products. Useable responses included 71 single entities and 24 combination products. the percentages of mode of product approval for the final sample were NDA 50%; ANDA, 16%, and grandfather clause, 34%. the mean life span was 20.4 years. the primary reasons for removal of the products were economic, 65%; regulatory, 27%, and other, 8%. There was a significant difference in the approval modes and a marginally significant difference for the reasons of product removal from the market for the two product types. the reason for product removal was different for products approved under the three modes of approval, but this was only marginally significant statistically. the X2 test was used for these determinations. More drug products were removed from the market than were ad...


Journal of Pharmaceutical Marketing & Management | 1990

Patronage Factors and Consumer Satisfaction with Sources of Prescription Purchases

Harry A. Smith; Stephen Joel Coons


The American Journal of Pharmaceutical Education | 1992

Motivational Factors Related to Decision on Pursuing Graduate Study.

Harry A. Smith


Journal of Pharmaceutical Marketing & Management | 1993

Patron Experience and Satisfaction with Pharmaceutical Services

Harry A. Smith; Stephen Joel Coons


Journal of The American Pharmaceutical Association | 1960

The Development of a Liquid Antihistaminic Preparation With Sustained Release Properties

Harry A. Smith; Robert V. Evanson; Glen J. Sperandio


The American Journal of Pharmaceutical Education | 1990

Pharmacists' Views of Congruence of Practice and Education and Related Issues.

Harry A. Smith


Journal of Pharmaceutical Marketing & Management | 1990

Changing Source of Prescription Purchases: A Patronage Loyalty Study

Harry A. Smith; Stephen Joel Coons


Archive | 1992

Marketing pharmaceutical services : patron loyalty, satisfaction, and preferences

Harry A. Smith; Stephen Joel Coons


The American Journal of Pharmaceutical Education | 1983

The Origin, Goals, and Development of a Clinical Pharmacy Emphasis in Pharmacy Education and Practice.

Harry A. Smith; Joseph V. Swintosky

Collaboration


Dive into the Harry A. Smith's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge